SARS-COV-2, İNFLUENZA VE RESPİRATUAR SİNSİTYAL VİRÜS PNÖMONİLERİ NEDENİYLE HASTANEDE YATAN HASTALARIN KLİNİK ÖZELLİKLERİNİN KARŞILAŞTIRILMASI

Yıl 2024, Cilt: 25 Sayı: 1 - OCAK 2024 SAYISI, 63 - 69, 17.01.2024

Gülbahar Darılmaz Yüce , Matin Iskandarov , Cemre Gündüz , Yaşar Ozan Saraçoğlu , Buğra Hatipoğlu , Cemile Cansu Alperen , Tuğba Yanık Yalçın , Tülin Yıldırım , Meriç Çolak , Gaye Ulubay , M. Şule Akçay

https://doi.org/10.18229/kocatepetip.1192685

Öz

AMAÇ: İnfluenza, respiratuar sinsityal virüs (RSV) ve şiddetli akut solunum yolu sendromu koronavirüs-2 (SARS-CoV-2) enfeksiyonu damlacıklar yoluyla yayılan, benzer semptom ve radyolojik bulguları olan ve solunum yetmezliğine neden olabilen etkenlerdir. Bu çalışma yeni koronavirüs hastalığı (COVID-19), influenza ve RSV pnömonisi olan hastaların klinik özelliklerini ve mortalite oranlarını karşılaştırmak için yapılmıştır.
GEREÇ VE YÖNTEM: Başkent Üniversitesi Tıp Fakültesi Hastanesi'nde COVID-19, influenza ve RSV pnömonisi nedeniyle yatırılan toplam 182 hasta çalışmaya dahil edildi. Hastalar klinik durumlarına göre gruplandırıldı. Hastaların demografik özellikleri, komorbiditeleri, laboratuvar ve radyolojik bulguları, solunum destek tedavileri ve mortalite oranları kaydedildi ve gruplar arasında karşılaştırıldı.
BULGULAR: Ortalama yaş COVID-19 grubunda (n:115) 69.4±7 yıl, influenza grubunda (n:33) 72,9±17,1 yıl ve RSV grubunda (n:34) 66,5±22,4 yıl idi. Gruplar arasında yaş farkı yoktu (p=0,305). COVID-19 grubunda erkek hastaların hastane yatış oranı daha fazlaydı (p=0,036). Komorbiditeler açısından gruplar arasında fark yoktu (p>0.05). COVID-19, RSV ve influenza hasta grupları arasında mortalite oranları açısından fark yoktu (p=0.260).
SONUÇ: Pulmoner tutulumlu viral enfeksiyonlar kötü klinik seyir gösterebildikleri için özel dikkat gerektirirler. İçinde bulunduğumuz yüzyılda ölümlere neden olan COVID-19 pnömonisinin klinik seyrinin şiddeti, influenza ve RSV gibi viral enfeksiyonların klinik seyrinden farklı değildir.

Anahtar Kelimeler

COVID-19, İnfluenza, Pnömoni, Solunum sinsityal virüsü

Destekleyen Kurum

Bu çalışma Başkent Üniversitesi Araştırma Fonu tarafınca desteklenmiştir.

Proje Numarası

KA20/452 – Tarih:15/12/2020

COMPARISON OF CLINICAL CHARACTERISTICS OF PATIENTS HOSPITALIZED DUE TO SARS-COV-2, INFLUENZA AND RESPIRATORY SYNCYTIAL VIRUS PNEUMONIA

Öz

OBJECTIVE: Influenza, respiratory syncytial virus (RSV), and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection are agents that spread through droplets, have similar symptoms and radiological findings, and can cause respiratory failure. This study was conducted to compare the clinical features and mortality rates of patients with novel coronavirus disease (COVID-19), influenza, and respiratory syncytial virus pneumonia.
MATERIAL AND METHODS: A total of 182 patients who were hospitalized at Baskent University Medical Faculty Hospital due to COVID-19, influenza, and RSV were included in the study. Patients were grouped according to their clinical status. Demographic characteristics, comorbidities, laboratory and radiological findings, respiratory support treatments and mortality rates of the patients were recorded and compared between the groups.
RESULTS: The mean age was 69.4±7 years in the COVID-19 group (n:115), 72.9±17.1 years in the influenza group (n:33), and 66.5±22.4 years in the RSV group (n:34). There was no difference in age between the groups (p=0.305). The hospitalization rate was higher for male patients in the COVID-19 group (p=0.036). There was no difference between the groups in terms of comorbidities (p>0.05). There was no difference in mortality rates between the COVID-19, RSV, and influenza patient groups (p=0.260).
CONCLUSIONS: Viral infections with pulmonary involvement require special attention because they can have a poor clinical course. The severity of the clinical course of COVID-19 pneumonia, which causes deaths in the current century, is not different from the clinical course of viral infections such as influenza and RSV.

Anahtar Kelimeler

COVID-19, Influenza, Pneumonia, Respiratory syncytial virus

Proje Numarası

KA20/452 – Tarih:15/12/2020

Kaynakça

• 1. Cavallazzi R. Ramirez JA. Influenza and viral pneumonia. Clin Chest Med. 2018;39(4):703-21.
• 2. Kim HJ, Choi SM, Lee J, et al. Respiratory virus of severe pneumonia in South Korea: Prevalence and clinical implications. PLoS One. 2018;13(6):e0198902.
• 3. Czubak J, Stolarczyk K, Orzeł A, et al. Comparison of the clinical differences between COVID-19, SARS, influenza, and the common cold: A systematic literature review. Adv Clin Exp Med. 2021;30(1):109-14.
• 4. T.C. Ministry of Health, General Directorate of Public Health, COVID-19 (SARS-CoV-2 Infection) Adult Patient Treatment. April 12, 2022, Ankara. Available from: https://covid19.saglik.gov.tr/Eklenti/43095/0/covid19rehberieriskinhastayonetimivetedavi-12042022pdf, Accessed date:08.03.2023.
• 5. Auvinen R, Nohynek H, Syrjänen R, et al. Comparison of the clinical characteristics and outcomes of hospitalized adult COVID-19 and influenza patients-a prospective observational study. Infect Dis (Lond). 2021;53(2):111-21.
• 6. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, et al. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020;11(1):29.
• 7. Ursin RL, Klein SL. Sex differences in respiratory viral pathogenesis and treatments. Annu Rev Virol. 2021;8(1):393-414.
• 8. Haber N. Respiratory syncytial virus infection in elderly adults. Med Mal Infect. 2018;48(6):377-82.
• 9. Vos LM, Oosterheert JJ, Hoepelman AIM, et al. External validation and update of a prognostic model to predict mortality in hospitalized adults with RSV: A retrospective Dutch cohort study. J Med Virol. 2019;91(12):2117-24.
• 10. Derksen-Lazet ND, Parmentier CEJ, Wildenbeest JG, et al; RESCEU Investigators. Patient involvement in RSV research: Towards patients setting the research agenda. J Infect Dis. 2022;226(1):130-34.
• 11. Colosia AD, Yang J, Hillson E, et al. The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: A systematic review. PLoS One. 2017;12(8):e0182321.
• 12. Garg S, Jain S, Dawood FS, et al. Pneumonia among adults hospitalized with laboratory-confirmed seasonal influenza virus infection-United States, 2005-2008. BMC Infect Dis. 2015 ;15:369.
• 13. Gao YD, Ding M, Dong X, et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76(2):428-55.
• 14. Ackerson B, Tseng HF, Sy LS, et al. Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults. Clin Infect Dis. 2019;69(2):197-203.
• 15. Talbot HK. Influenza in older adults. Infect Dis Clin North Am. 2017;31(4):757-66.
• 16. Walsh EE, Peterson DR, Falsey AR. Is clinical recognition of respiratory syncytial virus infection in hospitalized elderly and high-risk adults possible? J Infect Dis. 2007;195(7):1046-51.
• 17. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-69.
• 18. Cobb NL, Sathe NA, Duan KI, et al. Comparison of clinical features and outcomes in critically ill patients hospitalized with COVID-19 versus influenza. Ann Am Thorac Soc. 2021;18(4):632-40.
• 19. Torun Ş, Kesim Ç, Süner A, et al. Influenza viruses and SARS-CoV-2 in adult: 'Similarities and differences'. Tuberk Toraks. 2021;69(4):458-68.
• 20. Gao HN, Lu HZ, Cao B, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med. 2013;368(24):2277-85.
• 21. Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95(7):834-47.
• 22. Tang X, Du RH, Wang R, et al. Comparison of hospitalized patients with ARDS caused by COVID-19 and H1N1. Chest. 2020;158(1):195-205.
• 23. Onigbinde SO, Ojo AS, Fleary L, Hage R. Chest Computed tomography findings in COVID-19 and influenza: A Narrative Review. Biomed Res Int. 2020; (5): 6928368.
• 24. Kanne JP, Little BP, Chung JH, et al. Essentials for radiologists on COVID-19: An update-radiology scientific expert panel. Radiology. 2020;296(2):113-14.
• 25. Horby P, Lim WS, Emberson JR, et al. RECOVERY Collaborative Group Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384(8):693-704.
• 26. Noreen S, Maqbool I, Madni A. Dexamethasone: Therapeutic potential risks and future projection during COVID-19 pandemic. Eur J Pharmacol. 2021; 894:173854.